Tesamorelin evidence check
Tesamorelin reduces excess abdominal fat in adults with HIV-associated lipodystrophy.
Verdict
Supported with an evidence grade of A. Approved only within the narrow FDA-labeled context. Do not generalize to ordinary weight loss.
What this means
This grade applies only to the claim on this page, including the stated population and outcome. A supported claim in one context should not be stretched into a broader peptide promise.
What this does not mean
This page is not dosing guidance, a protocol, a recommendation to buy or use a product, or personal medical advice. High-risk claims need narrow wording, source links, and human review before publication.
Source trail
Evidence is listed by source type so you can see whether the claim rests on labeling, human studies, preclinical work, anecdotes, or vendor language.
EGRIFTA WR prescribing information
FDA labeling states that EGRIFTA WR is indicated for reducing excess abdominal fat in HIV-infected adults with lipodystrophy and is not indicated for weight loss management.
Open sourceDisclosure
Disclosure: Some links may be affiliate links. Peptide Fact Checks may earn a commission if you use them. That does not affect evidence grades, verdicts, or vendor transparency notes.